Hodgkin’s Lymphoma in Crohn’s Disease Treated with Infliximab

• Autor(a) principal: Carvalho,Diana
• Data de Publicação: 2017
• Outros Autores: Russo,Pedro, Bernardes,Carlos, Saiote,Joana, Ramos,Gonçalo, Mascarenhas,Luis, Borges,Nuno, Ramos,Jaime
• Tipo de documento: Relatório
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452017000600005
• topic: Crohn’s disease; Hodgkin’s disease; chemically induced; Infliximab; Lymphoproliferative disorders; Tumor necrosis factor-α

Introduction: Lymphoproliferative disorders, particularly non-Hodgkin’s and Hodgkin’s lymphomas, are rare in patients with inflammatory bowel diseases. The use of thiopurines and infection by Epstein-Barr virus are well-known cofactors that can raise its prevalence. Other risk factors such as disease activity and biological treatment are the subject of discussion, without enough data in the literature to confirm a potential association. Methods: We report a case of Hodgkin’s lymphoma in a patient who had been treated with azathioprine and was on long-term monotherapy with infliximab. Conclusions: We stress the importance of recognizing the possible occurrence of a lymphoproliferative disorder in association with anti-tumor necrosis factor-α therapy.